News September 7 2017

TiGenix has obtained a licence for commercial production at its Spanish facility

TiGenix has obtained a licence for the commercial production of expanded adipose-derived stem cells (eASCs) at its expanded manufacturing facility in Madrid, Spain, following an inspection by the Spanish Medicines Agency (AEMPS).